Akari Therapeutics, Plc (AKTX) |
|
0.2505 -0.005 (-2.07%)
|
03-24 16:00 |
|
Open: |
0.27 |
Pre. Close: |
0.2558 |
|
High:
|
0.27 |
Low:
|
0.2363 |
|
Volume:
|
108,454 |
Market Cap:
|
19(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:23:54 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 0.43  One year: 0.54 |
| Support: |
Support1: 0.21 Support2: 0.18 |
| Resistance: |
Resistance1: 0.37 Resistance2: 0.46 |
| Pivot: |
0.27 |
| Moving Average: |
MA(5): 0.24 MA(20): 0.28
MA(100): 0.45 MA(250): 0.78 |
| MACD: |
MACD(12,26): -0.1  Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 23 %D(3): 19.2 |
| RSI: |
RSI(14): 31.4 |
| 52-week: |
High: 1.61 Low: 0.21 |
| Average Vol(K): |
3-Month: 131 (K) 10-Days: 146 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AKTX ] has closed above bottom band by 30.2%. Bollinger Bands are 11.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.27 - 0.27 |
0.27 - 0.27 |
|
Low:
|
0.23 - 0.23 |
0.23 - 0.24 |
|
Close:
|
0.25 - 0.25 |
0.25 - 0.25 |
|
Company Description |
|
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom. |
Headline News |
Wed, 15 Feb 2023
Akari Therapeutics Announces Pre-Clinical Development Progress ... - GlobeNewswire
Tue, 22 Nov 2022
Akari Therapeutics to Participate in the Ophthalmology Day at BTIG - Yahoo Finance
Thu, 10 Nov 2022
Akari Therapeutics Granted FDA Rare Pediatric Disease ... - GlobeNewswire
Tue, 08 Nov 2022
Akari Therapeutics Announces the Appointment of John F. Neylan ... - GlobeNewswire
Tue, 20 Sep 2022
Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely? - Simply Wall St
Mon, 12 Sep 2022
Akari Therapeutics Announces $12.75 Million Registered Direct ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
74 (M) |
| Shares Float |
44 (M) |
|
% Held by Insiders
|
7.5 (%) |
|
% Held by Institutions
|
12.1 (%) |
|
Shares Short
|
92 (K) |
|
Shares Short P.Month
|
94 (K) |
Stock Financials |
|
EPS
|
-0.31 |
|
EPS Est Next Qtl
|
-0.67 |
|
EPS Est This Year
|
-2.36 |
|
EPS Est Next Year
|
-3.11 |
|
Book Value (p.s.)
|
0.14 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-142 |
|
Return on Equity (ttm)
|
-365.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.25 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-20 (M) |
|
Levered Free Cash Flow
|
-14 (M) |
Stock Valuations |
|
PE Ratio
|
-0.84 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.78 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.93 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
